Pfizer Inc. (NYSE:PFE) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Pfizer Inc. (NYSE:PFE) have earned a consensus rating of “Moderate Buy” from the sixteen research firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $32.92.

PFE has been the subject of a number of recent research reports. Sanford C. Bernstein assumed coverage on shares of Pfizer in a research report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price objective for the company. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Wednesday, October 23rd. StockNews.com downgraded Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Citigroup assumed coverage on Pfizer in a research note on Friday, October 25th. They set a “neutral” rating and a $30.00 price objective for the company. Finally, Wolfe Research began coverage on shares of Pfizer in a report on Friday, November 15th. They set an “underperform” rating and a $25.00 price target on the stock.

Pfizer Stock Up 0.1 %

Pfizer stock opened at $25.73 on Monday. The firm has a market cap of $145.81 billion, a price-to-earnings ratio of 34.77, a PEG ratio of 0.68 and a beta of 0.65. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer has a 12 month low of $24.48 and a 12 month high of $31.54. The stock has a fifty day simple moving average of $27.47 and a two-hundred day simple moving average of $28.38.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.42. The firm had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business’s quarterly revenue was up 31.2% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.17) EPS. Equities analysts predict that Pfizer will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 2nd. Investors of record on Friday, November 8th were given a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 6.53%. The ex-dividend date of this dividend was Friday, November 8th. Pfizer’s payout ratio is currently 227.03%.

Insider Activity

In other news, Director Scott Gottlieb acquired 1,000 shares of the business’s stock in a transaction on Wednesday, October 30th. The stock was bought at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the purchase, the director now owns 10,000 shares in the company, valued at approximately $282,400. This represents a 11.11 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 0.06% of the company’s stock.

Institutional Investors Weigh In On Pfizer

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. MFA Wealth Advisors LLC purchased a new stake in shares of Pfizer in the 2nd quarter valued at $29,000. Gladius Capital Management LP lifted its position in shares of Pfizer by 102.8% during the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 38,015 shares during the last quarter. Quarry LP acquired a new stake in shares of Pfizer during the second quarter worth about $31,000. Financial Connections Group Inc. acquired a new stake in shares of Pfizer in the second quarter valued at approximately $34,000. Finally, Teachers Insurance & Annuity Association of America acquired a new stake in shares of Pfizer during the third quarter worth about $35,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.